The Competition and Markets Authority (CMA) issued proceedings in the High Court of Justice, Business and Property Courts seeking the disqualification of Mr Pritesh Sonpal, a director of Lexon (UK).
The proceedings arise from the CMA’s decision dated 4 March 4, 2020, that between 2015 and 2017, Lexon, King Pharmaceuticals Limited, and Alissa Healthcare Research exchanged commercially sensitive information about prices for Nortriptyline Tablets, the volumes they were supplying, and Alissa’s plans to enter the market.
The CMA found that Lexon participated in the infringing behavior during the period from July 27, 2015, to May 27, 2016. Lexon have filed an appeal in the Competition Appeal Tribunal against CMA’s decision and the penalty imposed.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI